文献速递慢阻肺呼吸危重症与机械通气

英国慢阻肺急性加重后持续高碳酸血症患者家庭无创通气的成本效益

Cost-effectiveness of home non-invasive ventilation in patients with persistent hypercapnia after an acute exacerbation of COPD in the UK.
PubMed 文献 · Thorax · 2023-02-23

本研究基于一项已发表的疗效试验数据,评估英国医疗体系中家庭无创机械通气(HMV)联合家庭氧疗(HOT)用于慢阻肺急性加重后持续高碳酸血症患者的成本效益。QALYs由EQ-5D-5L计算得出。HOT-HMV在该临床人群中具有成本效益。

要点

  • HOT-HMV较单独HOT每患者每年多花费512英镑(95%CI 36至990英镑)。
  • 慢阻肺急性加重后持续高碳酸血症患者可从HOT-HMV中获益。

核心结论

  • 在英国医疗体系中,对于慢阻肺急性加重后持续高碳酸血症患者,HOT-HMV联合治疗相比单独HOT具有成本效益。

研究设计与样本

  • 基于一项已发表的疗效试验数据,评估英国医疗体系中HMV联合HOT的成本效益,QALYs由EQ-5D-5L计算。

主要发现

  • 计入所有直接患者成本后,HOT-HMV每患者每年比单独HOT贵512英镑(95%CI 36至990英镑)。

关键数值与推荐

  • 每患者每年成本差异为512英镑(95%CI 36至990英镑)。

临床怎么用

  • 对于慢阻肺急性加重后持续高碳酸血症患者,可考虑HOT-HMV联合治疗以改善生活质量并减少再入院。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Home non-invasive mechanical ventilation (HMV) with home oxygen therapy (HOT) in patients with persistent hypercapnia following an acute exacerbation of chronic obstructive pulmonary disease delays hospital readmission. The economic impact of this treatment is unknown. We evaluated the cost-effectiveness of HMV in the UK healthcare system using data from a previously published efficacy trial. Quality-adjusted life-years (QALYs) were computed from EQ-5D-5L. Accounting for all direct patient costs HOT-HMV was £512 (95%CI £36 to £990) more expensive per patient per year than HOT-alone. This small increase in cost was accompanied by increased quality of life leading to an incremental cost-effectiveness ratio of £10 259 per QALY. HOT-HMV was cost-effective in this clinical population. Trial registration number: NCT00990132.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Murphy, Brueggenjuergen, Reinhold, et al. Cost-effectiveness of home non-invasive ventilation in patients with persistent hypercapnia after an acute exacerbation of COPD in the UK. Thorax. 2023. PMID: 36823164. doi:10.1136/thorax-2022-219653

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。